Tag: DKN-01

Leap Therapeutics gets FDA orphan status for DKN-01 for gastric and gastroesophageal junction cancer

pharmanewsdaily- June 12, 2020

US immuno-oncology company Leap Therapeutics has been granted orphan drug designation for DKN-01 from the US Food and Drug Administration (FDA) for the treatment of ... Read More